share_log

AbbVie | 8-K/A: Poll Results of AbbVie Meeting (Amendment)

AbbVie | 8-K/A: Poll Results of AbbVie Meeting (Amendment)

艾伯維公司 | 8-K/A：艾伯維會議決議公告(修正)
美股sec公告 ·  05/09 05:06
牛牛AI助理已提取核心訊息
AbbVie Inc. has announced significant changes in its executive leadership, with Robert A. Michael set to take over as Chief Executive Officer from Richard A. Gonzalez on July 1, 2024. The transition was reported in a Form 8-K filed on February 20, 2024. Michael, who will also join the Board as a Class II director, will receive an annual base salary of $1.7 million, with the potential for a 150% bonus based on performance targets. Gonzalez will assume the role of Executive Chairman with an annual salary of $1.5 million. Additionally, at AbbVie's 2024 Annual Meeting of Stockholders on May 3, 2024, Class III directors were elected, Ernst & Young LLP was ratified as the independent accounting firm, and executive compensation was approved on an advisory basis. The company will hold future say on pay votes annually. However, proposals to eliminate supermajority voting, implement simple majority voting, and issue annual reports on lobbying and patent processes were not approved by stockholders.
AbbVie Inc. has announced significant changes in its executive leadership, with Robert A. Michael set to take over as Chief Executive Officer from Richard A. Gonzalez on July 1, 2024. The transition was reported in a Form 8-K filed on February 20, 2024. Michael, who will also join the Board as a Class II director, will receive an annual base salary of $1.7 million, with the potential for a 150% bonus based on performance targets. Gonzalez will assume the role of Executive Chairman with an annual salary of $1.5 million. Additionally, at AbbVie's 2024 Annual Meeting of Stockholders on May 3, 2024, Class III directors were elected, Ernst & Young LLP was ratified as the independent accounting firm, and executive compensation was approved on an advisory basis. The company will hold future say on pay votes annually. However, proposals to eliminate supermajority voting, implement simple majority voting, and issue annual reports on lobbying and patent processes were not approved by stockholders.
艾伯維公司宣佈了其執行領導層的重大變動，羅伯特·邁克爾定於2024年7月1日接替理查德·岡薩雷斯擔任首席執行官。過渡是在2024年2月20日提交的8-K表格中報告的。Michael還將以二級董事的身份加入董事會，他將獲得170萬美元的年基本工資，根據績效目標，有可能獲得150％的獎金。岡薩雷斯將擔任執行主席，年薪爲150萬美元。此外，在2024年5月3日的艾伯維2024年年度股東大會上，選舉了三類董事，安永會計師事務所被批准爲獨立會計師事務所，高管薪酬在諮詢基礎上獲得批准。該公司將對每年的薪酬投票擁有未來的發言權。但是，取消絕大多數投票、實施簡單多數投票以及發佈遊說和專利程序年度報告的提案沒有得到股東的批准。
艾伯維公司宣佈了其執行領導層的重大變動，羅伯特·邁克爾定於2024年7月1日接替理查德·岡薩雷斯擔任首席執行官。過渡是在2024年2月20日提交的8-K表格中報告的。Michael還將以二級董事的身份加入董事會，他將獲得170萬美元的年基本工資，根據績效目標，有可能獲得150％的獎金。岡薩雷斯將擔任執行主席，年薪爲150萬美元。此外，在2024年5月3日的艾伯維2024年年度股東大會上，選舉了三類董事，安永會計師事務所被批准爲獨立會計師事務所，高管薪酬在諮詢基礎上獲得批准。該公司將對每年的薪酬投票擁有未來的發言權。但是，取消絕大多數投票、實施簡單多數投票以及發佈遊說和專利程序年度報告的提案沒有得到股東的批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。